Portal de Periódicos da CAPES

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

2009; Springer Science+Business Media; Volume: 52; Issue: 9 Linguagem: Inglês

10.1007/s00125-009-1452-2

1432-0428

Julio Rosenstock, Vivian Fonseca, Janet B. McGill, Matthew C. Riddle, Jean‐Pierre Hallé, Irene Hramiak, P. Johnston, Janet L. Davis,

Chronic Lymphocytic Leukemia Research

To the Editor: We have reported a randomised, long-term safety study comparing the effects of using the insulin analogue glargine (A21Gly,B31Arg,B32Arg human insulin) versus human neutral protamine Hagedorn (NPH) insulin for 5 years in the management of type 2 diabetes [1].The study, in which 1017 patients were randomised and treated, was designed to assess ocular complications of diabetes: there was no excess of such effects with insulin glargine compared with NPH insulin treatment and there was a similar slow progression of diabetic retinopathy with both types of insulin.Because of recent concerns about postulated neoplastic effects of insulins [2-5], we report here additional information from our study that bears on this question.In total, the mean cumulative exposure in our study was more than 4 years (1,524 days in the insulin glargine group and 1,522 days in the NPH insulin group), with more than 70% of patients exposed to more than 4 years of treatment (76% and 71%, respectively) (Table 1).The baseline demographics and diabetes status were similar between the two treatment groups (insulin glargine vs NPH insulin): diabetes duration (10.7 vs 10.8 years),